Favorable Outcomes with TCAR vs. Carotid Endarterectomy in Patients with Carotid Artery Disease

Via: ​Globenewswire.com

Updated Results of TCAR Surveillance Project Presented at 2019 VEITHsymposium

NEW YORK, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the presentation of real-world data for the treatment of patients with carotid artery disease at risk for stroke at the VEITHsymposium. In a headline presentation, Dr. Mahmoud Malas of the University of California, San Diego School of Medicine shared updated results for the ongoing TransCarotid Artery Revascularization (TCAR) Surveillance Project contemporaneously comparing TCAR to the surgical standard of care, carotid endarterectomy (CEA).

​Read More: https://www.globenewswire.com/news-release/2019/11/22/1951528/0/en/Favorable-Outcomes-with-TCAR-vs-Carotid-Endarterectomy-in-Patients-with-Carotid-Artery-Disease.html